NextGen 2024: Refractory SJIA & MAS Session Part 2

NextGen 2024: Refractory SJIA & MAS Session Part 2

@SJIA_Foundation
@SJIA_Foundation
8 Followers
2 weeks ago 63

NextGen 2024: Refractory SJIA & MAS Session Part 2

@SJIA_Foundation2 weeks ago

Systemic Juvenile Idiopathic Arthritis: 
Resistant disease, UK experience
Paul Brogan
Professor …
1/7
.…Changing therapeutic landscape
2015 “interim” 
NHS Clinical 
Commissioning 
Policy 
2005 202…
2/7
Summary - GOSH experience of sJIA (n=76)
Overall sJIA outcome good – at last review (median 4.7 ye…
3/7
Complications: 2005-2021
Macrophage Activation Syndrome
• 46% (n=35/76) – At least one episode of…
4/7
Resistant disease: treatment 
Arthritis
Systemic 
inflammation
Smouldering/recurrent 
MAS
sJI…
5/7
Thank you
Front. Pediatr., Vol 11 (2023) 
https://doi.org/10.3389/fped.2023.1218312
6/7
sJIA/Still’s 
Switch to SC or IV 
Tocilizumab10
 Active systemic 
features?
YES
NO
Anakinra8…
7/7


  • Previous
  • Next
  • f Fullscreen
  • esc Exit Fullscreen
@SJIA_Foundation

Share

NextGen 2024: Refractory SJIA & MAS Session Part 2

Embed code


Swipe LEFT
to view Related

Scroll DOWN
to read doc

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.

Login

OR

Forgot password?

Don't have an account? Sign Up